NCT00578227 - Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects | Biotech Hunter

Enrollment

814

Participants

Timeline

Start Date

December 15, 2007

Primary Completion Date

December 1, 2008

Study Completion Date

April 28, 2009

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

Cervarix™

Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose

BIOLOGICAL

Twinrix ™ Paediatric

Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose

Trial Locations (21)

1032

GSK Investigational Site, Budapest

1033

GSK Investigational Site, Budapest

1039

GSK Investigational Site, Budapest

1089

GSK Investigational Site, Budapest

2970

GSK Investigational Site, Hoersholm

5000

GSK Investigational Site, Odense C

6723

GSK Investigational Site, Szeged

6795

GSK Investigational Site, Bordány

6800

GSK Investigational Site, Hódmezővásárhely

9024

GSK Investigational Site, Győr

9700

GSK Investigational Site, Szombathely

V3R 8P8

GSK Investigational Site, Surrey

L6T 3T1

GSK Investigational Site, Brampton

P3E 1H5

GSK Investigational Site, Greater Sudbury

L3Y 5G8

GSK Investigational Site, Newmarket

N7T 4X3

GSK Investigational Site, Sarnia

SE-371 41

GSK Investigational Site, Karlskrona

SE-581 85

GSK Investigational Site, Linköping

SE-921 82

GSK Investigational Site, Lycksele

SE-702 11

GSK Investigational Site, Örebro

SE-901 85

GSK Investigational Site, Umeå